The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel; The Edmond and Lily Safra Center for Brain Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Trends Pharmacol Sci. 2020 Nov;41(11):840-850. doi: 10.1016/j.tips.2020.09.003. Epub 2020 Oct 2.
Male-female differences have long been observed in the epidemiology and clinical presentation of psychiatric disorders. Current understanding is based on sex hormones and on transcription patterns governed by the sex chromosomes, and specific sexually dimorphic pathways were only recently identified. However, the underlying molecular mechanisms and pharmaceutical implications remain unclear. We highlight the importance of studying the sex-specific patterns of mental diseases at all levels from genomics to pharmaceutics. In particular, we discuss transcriptional level differences between the sexes in psychiatric disorders and outline the possible impact of such research on future pharmaceutical developments.
长期以来，在精神疾病的流行病学和临床表现方面，男女之间一直存在差异。目前的认识基于性激素和性染色体控制的转录模式，而特定的性别二态途径直到最近才被确定。然而，潜在的分子机制和药物影响仍不清楚。我们强调了从基因组学到药物学的各个层面研究精神疾病的性别特异性模式的重要性。特别是，我们讨论了精神疾病中性别之间转录水平的差异，并概述了此类研究对未来药物开发的可能影响。
